Characterize Immune Checkpoint Proteins and T Cell Exhaustion
Using Multiplex IHC
Advances in immuno-oncology have successfully led to novel cancer therapeutics with favorable patient responses that are more durable than conventional cytotoxic chemotherapy (1). However, not all patients respond to immunotherapy; therefore investigators are trying to identify clinically relevant biomarkers with the goal of developing therapeutics based on personalized medicine (2,3).
Spatial localization of multiple biomarkers is critical when cataloging subsets of immune infiltrate and cancer cells and their interactions in the tumor microenvironment. Multiplexed assays are required for investigations of multiple therapeutic targets and predictive biomarkers in limited and valuable patient samples. For these reasons, fluorescent multiplex immunohistochemistry (mIHC), which enables detection of 6 or more proteins/biomarkers in formalin-fixed, paraffin-embedded (FFPE) tissue samples, is a valuable tool for immuno-oncology.
In mIHC as well as in single/dual-plex chromogenic IHC approaches, using application-validated antibodies against relevant targets is crucial in order to obtain reliable results. Antibodies validated for IHC from CST enable investigators to get more information about biomarker expression, localization, interaction, and disease context.
Our mIHC app note and poster resources explore the protocol and technical considerations for selecting and using antibodies in mIHC to assess immune checkpoint proteins and T cell exhaustion in FFPE tissue samples.
1. Sharma, P. and Allison, J.P. (2015) Cell 161, 205–14.
2. Mahoney, K.M. and Atkins, M.B. (2014) Oncology (Williston Park) 28 (suppl 3), 39–48.
3. Masucci, G.V. et al. (2016) J Immunother Cancer 4, 76.